Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data

por Constantin, Joelle, Atanasov, Petar, Wirth, Daniel, Borsi, Andras
Publicado 2019

Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real‐world data analysis

por Banon, Tamar, Weil, Clara, Borsi, Andras, Chodick, Gabriel, Shakked, Zehavi, Barit Ben‐David, Nava
Publicado 2022

The cost burden of Crohn’s disease and ulcerative colitis depending on biologic treatment status – a Danish register-based study

por Alulis, Sarah, Vadstrup, Kasper, Olsen, Jens, Jørgensen, Tine Rikke, Qvist, Niels, Munkholm, Pia, Borsi, Andras
Publicado 2021

Extraintestinal Manifestations and Other Comorbidities in Ulcerative Colitis and Crohn Disease: A Danish Nationwide Registry Study 2003–2016

por Vadstrup, Kasper, Alulis, Sarah, Borsi, Andras, Jørgensen, Tine Rikke, Nielsen, Agnete, Munkholm, Pia, Qvist, Niels
Publicado 2020

Cost Burden of Crohn’s Disease and Ulcerative Colitis in the 10-Year Period Before Diagnosis—A Danish Register-Based Study From 2003–2015

por Vadstrup, Kasper, Alulis, Sarah, Borsi, Andras, Gustafsson, Nina, Nielsen, Agnete, Wennerström, E Christina M, Jørgensen, Tine Rikke, Qvist, Niels, Munkholm, Pia
Publicado 2020

Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary – a population-based study

por Kunovszki, Péter, Milassin, Ágnes, Gimesi-Országh, Judit, Takács, Péter, Szántó, Kata, Bálint, Anita, Farkas, Klaudia, Borsi, András, Lakatos, Péter L., Szamosi, Tamás, Molnár, Tamás
Publicado 2020

Burden of disease among patients with prevalent Crohn’s disease: results from a large German sickness fund

por Zhuleku, Evi, Antolin-Fontes, Beatriz, Borsi, Andras, Nissinen, Riikka, Bravatà, Ivana, Barthelmes, Jennifer Norma, Lee, Jennifer, Passey, Alun, Wirth, Daniel, Maywald, Ulf, Bokemeyer, Bernd, Wilke, Thomas, Ghiani, Marco
Publicado 2023

Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn’s Disease patients: A retrospective analysis using German claims data

por Zhuleku, Evi, Antolin-Fontes, Beatriz, Borsi, Andras, Nissinen, Riikka, Bravatà, Ivana, Barthelmes, Jennifer Norma, Le Bars, Manuela, Lee, Jennifer, Passey, Alun, Maywald, Ulf, Deiters, Barthold, Bokemeyer, Bernd, Wilke, Thomas, Ghiani, Marco
Publicado 2022

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort

por af Björkesten, Clas-Göran, Ilus, Tuire, Hallinen, Taru, Soini, Erkki, Eberl, Anja, Hakala, Kalle, Heikura, Mikko, Jussila, Airi, Koskela, Ritva, Koskinen, Inka, Moilanen, Veikko, Nielsen, Christian, Nieminen, Urpo, Nuutinen, Heikki, Heikkinen, Markku, Suhonen, Ulla-Maija, Tillonen, Jyrki, Utriainen, Karri, Vihriälä, Ilkka, Wennerström, Christina, Borsi, Andras, Nissinen, Riikka, Koivunen, Minni R., Sipponen, Taina
Publicado 2020